Compare KMT & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | STOK |
|---|---|---|
| Founded | 1938 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | N/A | 2019 |
| Metric | KMT | STOK |
|---|---|---|
| Price | $33.67 | $30.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $29.67 | ★ $34.50 |
| AVG Volume (30 Days) | 776.6K | ★ 813.5K |
| Earning Date | 02-04-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.22 | 0.68 |
| Revenue | ★ $1,982,871,000.00 | $205,632,000.00 |
| Revenue This Year | $9.06 | $430.24 |
| Revenue Next Year | $4.15 | N/A |
| P/E Ratio | ★ $27.27 | $44.66 |
| Revenue Growth | N/A | ★ 1128.17 |
| 52 Week Low | $17.30 | $5.35 |
| 52 Week High | $34.14 | $38.69 |
| Indicator | KMT | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 82.67 | 45.38 |
| Support Level | $28.93 | $25.21 |
| Resistance Level | $34.14 | $37.34 |
| Average True Range (ATR) | 0.76 | 1.89 |
| MACD | 0.36 | -0.42 |
| Stochastic Oscillator | 92.14 | 43.28 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.